Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Tisotumab Vedotin
Indication/Tumor Type prostate cancer
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable Tisotumab Vedotin Case Reports/Case Series Actionable In a Phase II trial, Tisotumab vedotin treatment resulted in prolonged stable disease in 2 patients with prostate cancer (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 2570-2570; NCT02001623). detail...
PubMed Id Reference Title Details
A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors. Full reference...